文章摘要
郭 武,田 霞,任 伟,何文均,刘 泉.莫西沙星联合纤维支气管镜药物灌注对耐多药肺结核患者T细胞亚群、肺功能和肝功能的影响[J].,2021,(8):1541-1544
莫西沙星联合纤维支气管镜药物灌注对耐多药肺结核患者T细胞亚群、肺功能和肝功能的影响
The Effect of Moxifloxacin Combined with Fiberbronchoscopy on T Cell Subsets, Lung Function and Liver Function in Multidrug Resistant Tuberculosis Patients
投稿时间:2020-10-07  修订日期:2020-10-30
DOI:10.13241/j.cnki.pmb.2021.08.031
中文关键词: 纤维支气管镜药物灌注  T细胞亚群  肺功能  莫西沙星  肝功能  耐多药肺结核
英文关键词: Bronchofiberscope drug perfusion  T cell subsets  Pulmonary function  Moxifloxacin  Liver function  Multidrug resistant tuberculosis
基金项目:重庆市涪陵区科技计划项目(FLKJ,2019ABB2032)
作者单位E-mail
郭 武 重庆市涪陵中心医院感染科 重庆 408000 guowu1974@163.com 
田 霞 重庆市涪陵中心医院感染科 重庆 408000  
任 伟 重庆市涪陵中心医院感染科 重庆 408000  
何文均 重庆市涪陵中心医院感染科 重庆 408000  
刘 泉 重庆市涪陵中心医院感染科 重庆 408000  
摘要点击次数: 20
全文下载次数: 25
中文摘要:
      摘要 目的:探讨莫西沙星联合纤维支气管镜药物灌注对耐多药肺结核患者T细胞亚群、肺功能和肝功能的影响。方法:选取2017年2月~2018年12月期间我院收治的90例耐多药肺结核患者,根据随机数字表法分为对照组(n=45,常规基础治疗)和研究组(n=45,莫西沙星联合纤维支气管镜药物灌注),比较两组患者痰菌转阴率、病灶吸收率、T细胞亚群、肺功能和肝功能。结果:研究组治疗6个月后的痰菌转阴率为88.89%(40/45),高于对照组的68.89%(31/45)(P<0.05)。研究组治疗6个月后的病灶吸收率为84.44%(38/45),高于对照组的64.44%(29/45)(P<0.05)。两组治疗6个月后第1 s用力呼气容积(FEV1)、用力肺活量(FVC)、每分钟最大通气量(MVV)占预计值百分比、总蛋白(TP)、CD4+、CD4+/CD8+均升高,且研究组高于对照组(P<0.05);丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、CD8+均降低,且研究组低于对照组(P<0.05)。结论:莫西沙星联合纤维支气管镜药物灌注治疗耐多药肺结核,可有效阻止疾病进展,同时在改善患者T细胞亚群、肺功能和肝功能方面效果显著。
英文摘要:
      ABSTRACT Objective: To investigate the effect of moxifloxacin combined with bronchofiberscope on T cell subsets, lung function and liver function in Multidrug resistant tuberculosis patients. Methods: 90 Multidrug resistant tuberculosis patients in our hospital from February 2017 to December 2018 were selectd, they were divided into control group (n=45, routine basic treatment) and study group (n=45, moxifloxacin combined with bronchofiberscope drug perfusion) according to the random number table method. The sputum negative rate, focus absorption rate, T cell subsets, lung function and liver function were compared between the two groups. Results: The sputum negative rate of the study group was 88.89% (40/45), which was higher than 68.89% (31/45) of the control group (P<0.05). The absorption rate of focus in the study group was 84.44% (38/45), which was higher than 64.44% (29/45) in the control group (P<0.05). After 6 months of treatment, forced expiratory volume (FEV1), forced vital capacity (FVC), and maximum ventilation volume per minute (MVV) as a percentage of the predicted value, the total protein (TP), CD4+, CD4+/ CD8+ in the first second in the two groups were higher than those of the control group, and the study group were higher than the control group (P<0.05). Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and CD8+ decreased, and the study group was lower than that in the control group(P<0.05). Conclusion: Moxifloxacin combined with fiberbronchoscopic drug perfusion can effectively prevent the progress of the disease and improve the T cell subsets, lung function and liver function of the patients.
查看全文   查看/发表评论  下载PDF阅读器
关闭